CRBU Long Put Strategy

CRBU (Caribou Biosciences, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.

CRBU (Caribou Biosciences, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $210.3M, a beta of 2.27 versus the broader market, a 52-week range of 0.769-3.535, average daily share volume of 1.4M, a public-listing history dating back to 2021, approximately 147 full-time employees. These structural characteristics shape how CRBU stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 2.27 indicates CRBU has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a long put on CRBU?

A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration.

Current CRBU snapshot

As of May 15, 2026, spot at $2.13, ATM IV 123.80%, IV rank 25.82%, expected move 35.49%. The long put on CRBU below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this long put structure on CRBU specifically: CRBU IV at 123.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a CRBU long put, with a market-implied 1-standard-deviation move of approximately 35.49% (roughly $0.76 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CRBU expiries trade a higher absolute premium for lower per-day decay. Position sizing on CRBU should anchor to the underlying notional of $2.13 per share and to the trader's directional view on CRBU stock.

CRBU long put setup

The CRBU long put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CRBU near $2.13, the first option leg uses a $2.13 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CRBU chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CRBU shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Put$2.13N/A

CRBU long put risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium.

CRBU long put payoff curve

Modeled P&L at expiration across a range of underlying prices for the long put on CRBU. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long put on CRBU

Long puts on CRBU hedge an existing long CRBU stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying CRBU exposure being hedged.

CRBU thesis for this long put

The market-implied 1-standard-deviation range for CRBU extends from approximately $1.37 on the downside to $2.89 on the upside. A CRBU long put expresses a directional view that the underlying closes below the strike minus premium at expiration, frequently sized to hedge an existing long CRBU position with one put per 100 shares held. Current CRBU IV rank near 25.82% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CRBU at 123.80%. As a Healthcare name, CRBU options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CRBU-specific events.

CRBU long put positions are structurally bearish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CRBU positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CRBU alongside the broader basket even when CRBU-specific fundamentals are unchanged. Long-premium structures like a long put on CRBU are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current CRBU chain quotes before placing a trade.

Frequently asked questions

What is a long put on CRBU?
A long put on CRBU is the long put strategy applied to CRBU (stock). The strategy is structurally bearish: A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration. With CRBU stock trading near $2.13, the strikes shown on this page are snapped to the nearest listed CRBU chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are CRBU long put max profit and max loss calculated?
Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium. For the CRBU long put priced from the end-of-day chain at a 30-day expiry (ATM IV 123.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a CRBU long put?
The breakeven for the CRBU long put priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current CRBU market-implied 1-standard-deviation expected move is approximately 35.49%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long put on CRBU?
Long puts on CRBU hedge an existing long CRBU stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying CRBU exposure being hedged.
How does current CRBU implied volatility affect this long put?
CRBU ATM IV is at 123.80% with IV rank near 25.82%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related CRBU analysis